Randomized controlled trial of screening for hepatocellular carcinoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-03-20

AUTHORS

Bo-Heng Zhang, Bing-Hui Yang, Zhao-You Tang

ABSTRACT

Purpose Screening for hepatocellular carcinoma (HCC) has been conducted for over 20 years, but there is no conclusive evidence that screening may reduce HCC mortality. The aim of this study was to assess the effect of screening on HCC mortality in people at increased risk.Methods This study included 18,816 people, aged 35–59 years with hepatitis B virus infection or a history of chronic hepatitis in urban Shanghai, China. Participants were randomly allocated to a screening (9,373) or control (9,443) group. Controls received no screening and continued to use health-care facilities. Screening group participants were invited to have an AFP test and ultrasonography examination every 6 months. Screening was stopped in December 1997; by that time screening group participants had been offered five to ten times. All participants were followed up until December 1998. The primary outcome measure was HCC mortality.Results The screened group completed 58.2 percent of the screening offered. When the screening group was compared to the control group, the number of HCC was 86 versus 67; subclinical HCC being 52 (60.5%) versus 0; small HCC 39 (45.3%) versus 0; resection achieved 40 (46.5%) versus 5 (7.5%); 1-, 3,-, and 5-year survival rate 65.9%, 52.6%, 46.4% versus 31.2%, 7.2%, 0, respectively. Thirty-two people died from HCC in the screened group versus 54 in the control group, and the HCC mortality rate was significantly lower in the screened group than in controls, being 83.2/100,000 and 131.5/100,000, respectively, with a mortality rate ratio of 0.63 (95%CI 0.41–0.98).Conclusions Our finding indicated that biannual screening reduced HCC mortality by 37%. More... »

PAGES

417-422

References to SciGraph publications

  • 1997-06. Prospective study of early detection for primary liver cancer in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0

    DOI

    http://dx.doi.org/10.1007/s00432-004-0552-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1005026117

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/15042359


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Public Health and Health Services", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Biomarkers, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Carcinoma, Hepatocellular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "China", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Incidence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mass Screening", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasm Staging", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Survival Rate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ultrasonography", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Urban Population", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "alpha-Fetoproteins", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China", 
              "id": "http://www.grid.ac/institutes/grid.413087.9", 
              "name": [
                "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Zhang", 
            "givenName": "Bo-Heng", 
            "id": "sg:person.0741146613.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741146613.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China", 
              "id": "http://www.grid.ac/institutes/grid.413087.9", 
              "name": [
                "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yang", 
            "givenName": "Bing-Hui", 
            "id": "sg:person.0761714654.79", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761714654.79"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China", 
              "id": "http://www.grid.ac/institutes/grid.413087.9", 
              "name": [
                "Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tang", 
            "givenName": "Zhao-You", 
            "id": "sg:person.015352132727.21", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015352132727.21"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf01438313", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023430516", 
              "https://doi.org/10.1007/bf01438313"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-03-20", 
        "datePublishedReg": "2004-03-20", 
        "description": "Purpose Screening for hepatocellular carcinoma (HCC) has been conducted for over 20\u00a0years, but there is no conclusive evidence that screening may reduce HCC mortality. The aim of this study was to assess the effect of screening on HCC mortality in people at increased risk.Methods This study included 18,816 people, aged 35\u201359\u00a0years with hepatitis B virus infection or a history of chronic hepatitis in urban Shanghai, China. Participants were randomly allocated to a screening (9,373) or control (9,443) group. Controls received no screening and continued to use health-care facilities. Screening group participants were invited to have an AFP test and ultrasonography examination every 6\u00a0months. Screening was stopped in December 1997; by that time screening group participants had been offered five to ten times. All participants were followed up until December 1998. The primary outcome measure was HCC mortality.Results The screened group completed 58.2 percent of the screening offered. When the screening group was compared to the control group, the number of HCC was 86 versus 67; subclinical HCC being 52 (60.5%) versus 0; small HCC 39 (45.3%) versus 0; resection achieved 40 (46.5%) versus 5 (7.5%); 1-, 3,-, and 5-year survival rate 65.9%, 52.6%, 46.4% versus 31.2%, 7.2%, 0, respectively. Thirty-two people died from HCC in the screened group versus 54 in the control group, and the HCC mortality rate was significantly lower in the screened group than in controls, being 83.2/100,000 and 131.5/100,000, respectively, with a mortality rate ratio of 0.63 (95%CI 0.41\u20130.98).Conclusions Our finding indicated that biannual screening reduced HCC mortality by 37%.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00432-004-0552-0", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1313647", 
            "issn": [
              "0171-5216", 
              "1432-1335"
            ], 
            "name": "Journal of Cancer Research and Clinical Oncology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "7", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "130"
          }
        ], 
        "keywords": [
          "hepatocellular carcinoma", 
          "HCC mortality", 
          "control group", 
          "screened group", 
          "hepatitis B virus infection", 
          "number of HCC", 
          "subclinical hepatocellular carcinoma", 
          "primary outcome measure", 
          "mortality rate ratios", 
          "group participants", 
          "health-care facilities", 
          "HCC mortality rates", 
          "chronic hepatitis", 
          "screening group", 
          "ultrasonography examination", 
          "virus infection", 
          "outcome measures", 
          "biannual screening", 
          "AFP test", 
          "mortality rate", 
          "mortality", 
          "rate ratio", 
          "carcinoma", 
          "urban Shanghai", 
          "screening", 
          "participants", 
          "group", 
          "conclusive evidence", 
          "hepatitis", 
          "resection", 
          "years", 
          "infection", 
          "trials", 
          "months", 
          "risk", 
          "control", 
          "study", 
          "examination", 
          "people", 
          "conclusion", 
          "percent", 
          "aim", 
          "findings", 
          "evidence", 
          "history", 
          "time", 
          "measures", 
          "rate", 
          "test", 
          "effect", 
          "number", 
          "ratio", 
          "facilities", 
          "results", 
          "Shanghai", 
          "method", 
          "China", 
          "Purpose Screening", 
          "B virus infection", 
          "Screening group participants", 
          "small HCC 39", 
          "HCC 39", 
          "survival rate 65.9", 
          "rate 65.9"
        ], 
        "name": "Randomized controlled trial of screening for hepatocellular carcinoma", 
        "pagination": "417-422", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1005026117"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00432-004-0552-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "15042359"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00432-004-0552-0", 
          "https://app.dimensions.ai/details/publication/pub.1005026117"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:14", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_394.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00432-004-0552-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-004-0552-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    208 TRIPLES      22 PREDICATES      107 URIs      98 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00432-004-0552-0 schema:about N0ea6650e6b9b4bc2822394ac0e69a03a
    2 N1242cc6e446746068611e6eba87ec77b
    3 N22e97b7b987049c9a8dbc9fe27b29569
    4 N2dda442c3622407586db045cf1de46dc
    5 N31f186defd3a4bce9781d7efa0dea90f
    6 N536db6b29ae04e2d9d49e0b132e76be3
    7 N7fb81dbe1a5c4eed842f0c879c4b124d
    8 N8bb55e0067804809a68a3784c85655d6
    9 Na6c6816c1ae641cabdc28c5a9e11bad0
    10 Nd0d904ab2c7746d79d0957bdcc71d91a
    11 Nd62d6f7775ac47ab9ee50d634ad3a26f
    12 Nd8479fb35a124a64a672e706d8466965
    13 Nddbd62af5498458f8c4a74cf6d1cfcd9
    14 Nf109b3a431634ab291f65cd2f34bfd25
    15 Nf2e183283d1c4b40a54442fb2374fa7b
    16 Nfcd5f11f2df24af29b3ddaa9f31effdc
    17 anzsrc-for:11
    18 anzsrc-for:1117
    19 schema:author Nbd7181b773004c64ac7412e69be52c16
    20 schema:citation sg:pub.10.1007/bf01438313
    21 schema:datePublished 2004-03-20
    22 schema:datePublishedReg 2004-03-20
    23 schema:description Purpose Screening for hepatocellular carcinoma (HCC) has been conducted for over 20 years, but there is no conclusive evidence that screening may reduce HCC mortality. The aim of this study was to assess the effect of screening on HCC mortality in people at increased risk.Methods This study included 18,816 people, aged 35–59 years with hepatitis B virus infection or a history of chronic hepatitis in urban Shanghai, China. Participants were randomly allocated to a screening (9,373) or control (9,443) group. Controls received no screening and continued to use health-care facilities. Screening group participants were invited to have an AFP test and ultrasonography examination every 6 months. Screening was stopped in December 1997; by that time screening group participants had been offered five to ten times. All participants were followed up until December 1998. The primary outcome measure was HCC mortality.Results The screened group completed 58.2 percent of the screening offered. When the screening group was compared to the control group, the number of HCC was 86 versus 67; subclinical HCC being 52 (60.5%) versus 0; small HCC 39 (45.3%) versus 0; resection achieved 40 (46.5%) versus 5 (7.5%); 1-, 3,-, and 5-year survival rate 65.9%, 52.6%, 46.4% versus 31.2%, 7.2%, 0, respectively. Thirty-two people died from HCC in the screened group versus 54 in the control group, and the HCC mortality rate was significantly lower in the screened group than in controls, being 83.2/100,000 and 131.5/100,000, respectively, with a mortality rate ratio of 0.63 (95%CI 0.41–0.98).Conclusions Our finding indicated that biannual screening reduced HCC mortality by 37%.
    24 schema:genre article
    25 schema:inLanguage en
    26 schema:isAccessibleForFree false
    27 schema:isPartOf N47ef6a17e16443f6905589d2862c3e0d
    28 N7edf10d24e274767a4504d72da92e73f
    29 sg:journal.1313647
    30 schema:keywords AFP test
    31 B virus infection
    32 China
    33 HCC 39
    34 HCC mortality
    35 HCC mortality rates
    36 Purpose Screening
    37 Screening group participants
    38 Shanghai
    39 aim
    40 biannual screening
    41 carcinoma
    42 chronic hepatitis
    43 conclusion
    44 conclusive evidence
    45 control
    46 control group
    47 effect
    48 evidence
    49 examination
    50 facilities
    51 findings
    52 group
    53 group participants
    54 health-care facilities
    55 hepatitis
    56 hepatitis B virus infection
    57 hepatocellular carcinoma
    58 history
    59 infection
    60 measures
    61 method
    62 months
    63 mortality
    64 mortality rate
    65 mortality rate ratios
    66 number
    67 number of HCC
    68 outcome measures
    69 participants
    70 people
    71 percent
    72 primary outcome measure
    73 rate
    74 rate 65.9
    75 rate ratio
    76 ratio
    77 resection
    78 results
    79 risk
    80 screened group
    81 screening
    82 screening group
    83 small HCC 39
    84 study
    85 subclinical hepatocellular carcinoma
    86 survival rate 65.9
    87 test
    88 time
    89 trials
    90 ultrasonography examination
    91 urban Shanghai
    92 virus infection
    93 years
    94 schema:name Randomized controlled trial of screening for hepatocellular carcinoma
    95 schema:pagination 417-422
    96 schema:productId N1b892dfa37c74ed1a8999af8f82f17b5
    97 N358f4c9529444edd89ab506d04a75af1
    98 N7d012066d4c04d42933465058e245ac4
    99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005026117
    100 https://doi.org/10.1007/s00432-004-0552-0
    101 schema:sdDatePublished 2022-01-01T18:14
    102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    103 schema:sdPublisher N985a75a9f2014a689b4e84fbad464d5b
    104 schema:url https://doi.org/10.1007/s00432-004-0552-0
    105 sgo:license sg:explorer/license/
    106 sgo:sdDataset articles
    107 rdf:type schema:ScholarlyArticle
    108 N0ea6650e6b9b4bc2822394ac0e69a03a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Liver Neoplasms
    110 rdf:type schema:DefinedTerm
    111 N1242cc6e446746068611e6eba87ec77b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    112 schema:name Survival Rate
    113 rdf:type schema:DefinedTerm
    114 N1b892dfa37c74ed1a8999af8f82f17b5 schema:name dimensions_id
    115 schema:value pub.1005026117
    116 rdf:type schema:PropertyValue
    117 N22e97b7b987049c9a8dbc9fe27b29569 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    118 schema:name Urban Population
    119 rdf:type schema:DefinedTerm
    120 N2dda442c3622407586db045cf1de46dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Female
    122 rdf:type schema:DefinedTerm
    123 N31f186defd3a4bce9781d7efa0dea90f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    124 schema:name Carcinoma, Hepatocellular
    125 rdf:type schema:DefinedTerm
    126 N358f4c9529444edd89ab506d04a75af1 schema:name pubmed_id
    127 schema:value 15042359
    128 rdf:type schema:PropertyValue
    129 N47ef6a17e16443f6905589d2862c3e0d schema:volumeNumber 130
    130 rdf:type schema:PublicationVolume
    131 N536db6b29ae04e2d9d49e0b132e76be3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    132 schema:name Humans
    133 rdf:type schema:DefinedTerm
    134 N66383904029a41929be1d30de618fe8a rdf:first sg:person.015352132727.21
    135 rdf:rest rdf:nil
    136 N7d012066d4c04d42933465058e245ac4 schema:name doi
    137 schema:value 10.1007/s00432-004-0552-0
    138 rdf:type schema:PropertyValue
    139 N7edf10d24e274767a4504d72da92e73f schema:issueNumber 7
    140 rdf:type schema:PublicationIssue
    141 N7fb81dbe1a5c4eed842f0c879c4b124d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Incidence
    143 rdf:type schema:DefinedTerm
    144 N8bb55e0067804809a68a3784c85655d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Ultrasonography
    146 rdf:type schema:DefinedTerm
    147 N985a75a9f2014a689b4e84fbad464d5b schema:name Springer Nature - SN SciGraph project
    148 rdf:type schema:Organization
    149 N9dac4fb381fc47e4a0f828051148dcab rdf:first sg:person.0761714654.79
    150 rdf:rest N66383904029a41929be1d30de618fe8a
    151 Na6c6816c1ae641cabdc28c5a9e11bad0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Adult
    153 rdf:type schema:DefinedTerm
    154 Nbd7181b773004c64ac7412e69be52c16 rdf:first sg:person.0741146613.54
    155 rdf:rest N9dac4fb381fc47e4a0f828051148dcab
    156 Nd0d904ab2c7746d79d0957bdcc71d91a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Mass Screening
    158 rdf:type schema:DefinedTerm
    159 Nd62d6f7775ac47ab9ee50d634ad3a26f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name alpha-Fetoproteins
    161 rdf:type schema:DefinedTerm
    162 Nd8479fb35a124a64a672e706d8466965 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Middle Aged
    164 rdf:type schema:DefinedTerm
    165 Nddbd62af5498458f8c4a74cf6d1cfcd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name China
    167 rdf:type schema:DefinedTerm
    168 Nf109b3a431634ab291f65cd2f34bfd25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Biomarkers, Tumor
    170 rdf:type schema:DefinedTerm
    171 Nf2e183283d1c4b40a54442fb2374fa7b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Neoplasm Staging
    173 rdf:type schema:DefinedTerm
    174 Nfcd5f11f2df24af29b3ddaa9f31effdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Male
    176 rdf:type schema:DefinedTerm
    177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    178 schema:name Medical and Health Sciences
    179 rdf:type schema:DefinedTerm
    180 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
    181 schema:name Public Health and Health Services
    182 rdf:type schema:DefinedTerm
    183 sg:journal.1313647 schema:issn 0171-5216
    184 1432-1335
    185 schema:name Journal of Cancer Research and Clinical Oncology
    186 schema:publisher Springer Nature
    187 rdf:type schema:Periodical
    188 sg:person.015352132727.21 schema:affiliation grid-institutes:grid.413087.9
    189 schema:familyName Tang
    190 schema:givenName Zhao-You
    191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015352132727.21
    192 rdf:type schema:Person
    193 sg:person.0741146613.54 schema:affiliation grid-institutes:grid.413087.9
    194 schema:familyName Zhang
    195 schema:givenName Bo-Heng
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741146613.54
    197 rdf:type schema:Person
    198 sg:person.0761714654.79 schema:affiliation grid-institutes:grid.413087.9
    199 schema:familyName Yang
    200 schema:givenName Bing-Hui
    201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761714654.79
    202 rdf:type schema:Person
    203 sg:pub.10.1007/bf01438313 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023430516
    204 https://doi.org/10.1007/bf01438313
    205 rdf:type schema:CreativeWork
    206 grid-institutes:grid.413087.9 schema:alternateName Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China
    207 schema:name Liver Cancer Institute of Fudan University, Zhongshan Hospital, 180 Feng Lin Road, Shanghai, 200032, China
    208 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...